Dr. Yamini is a true UChicago product — he trained here as a resident, rose to full Professor, and now holds joint appointments in both Neurological Surgery and Radiation and Cellular Oncology. His NIH-funded laboratory has spent years unraveling how the NF-kB signaling pathway drives treatment resistance in glioblastoma, identifying CDK1 as a druggable target to enhance chemotherapy response. He's also developing biodegradable nanoparticle vectors to deliver drugs directly to brain tumors — bypassing the blood-brain barrier that makes most chemotherapy ineffective against brain cancer. He is currently leading a multi-institutional Phase I trial combining acetazolamide with temozolomide for newly diagnosed malignant gliomas. He speaks English, Farsi, and Spanish.
Our team will review your case and help you take the next step.
Call (773) 702-2123